journal
MENU ▼
Read by QxMD icon Read
search

American Health & Drug Benefits

journal
https://www.readbyqxmd.com/read/27625745/oncologist-support-for-consolidated-payments-for-cancer-care-management-in-the-united-states
#1
Siva Narayanan, Emily Hautamaki
BACKGROUND: The cost of cancer care in the United States continues to rise, with pressure on oncologists to provide high-quality, cost-effective care while maintaining the financial stability of their practice. Existing payment models do not typically reward care coordination or quality of care. In May 2014, the American Society of Clinical Oncology (ASCO) released a payment reform proposal (revised in May 2015) that includes a new payment structure for quality-of-care performance metrics...
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625744/hospital-and-health-plan-partnerships-the-affordable-care-act-s-impact-on-promoting-health-and-wellness
#2
Michelle Vu, Annesha White, Virginia P Kelley, Jennifer Kuca Hopper, Cathy Liu
BACKGROUND: The Affordable Care Act (ACA) healthcare reforms, centered on achieving the Centers for Medicare & Medicaid Services (CMS) Triple Aim goals of improving patient care quality and satisfaction, improving population health, and reducing costs, have led to increasing partnerships between hospitals and insurance companies and the implementation of employee wellness programs. Hospitals and insurance companies have opted to partner to distribute the risk and resources and increase coordination of care...
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625743/impact-of-pharmacist-provided-medication-therapy-management-on-healthcare-quality-and-utilization-in-recently-discharged-elderly-patients
#3
Jordan D Haag, Amanda Z Davis, Robert W Hoel, Jeffrey J Armon, Laura J Odell, Ross A Dierkhising, Paul Y Takahashi
BACKGROUND: The optimization of medication use during care transitions represents an opportunity to improve overall health-related outcomes. The utilization of clinical pharmacists during care transitions has demonstrated benefit, although the optimal method of integration during the care transition process remains unclear. OBJECTIVE: To evaluate the impact of pharmacist-provided telephonic medication therapy management (MTM) on care quality in a care transitions program (CTP) for high-risk older adults...
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625742/improving-population-health-by-working-with-communities
#4
EDITORIAL
David B Nash
No abstract text is available yet for this article.
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688835/innovation-tops-current-trends-in-the-2016-oncology-drug-pipeline
#5
Dalia Buffery
No abstract text is available yet for this article.
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688834/thromboembolic-events-associated-with-bevacizumab-plus-chemotherapy-for-patients-with-colorectal-cancer-a-meta-analysis-of-randomized-controlled-trials
#6
Abdullah K Alahmari, Ziyad S Almalki, Ahmed K Alahmari, Jeff J Guo
BACKGROUND: Bevacizumab is a recombinant, humanized monoclonal antibody that hinders the proliferation of new blood vessels required for malignant progression. The drug is considered safe and tolerable; however, some controversy remains about whether it is linked to venous and arterial thromboembolic events (TEEs). OBJECTIVE: To evaluate the risk for overall, venous, and arterial TEEs in patients with colorectal cancer (CRC) who are administered bevacizumab plus chemotherapy in randomized controlled trials (RCTs)...
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688833/economic-burden-of-toxicities-associated-with-treating-metastatic-melanoma-in-the-united-states
#7
S Pinar Bilir, Qiufei Ma, Zhongyun Zhao, Elizabeth Wehler, Julie Munakata, Beth Barber
BACKGROUND: Little has been reported on the costs of managing the adverse events (AEs) associated with current therapies for patients with regional or distant metastatic melanoma. OBJECTIVES: To identify treatment-related AEs in patients with metastatic melanoma and to estimate the associated costs of treating these AEs in the United States. METHODS: A cost-estimation study for AEs associated with treatment of metastatic melanoma was conducted from 2012 to 2013 by identifying grades 3 and 4 AEs through the use of a comprehensive search of drug labels and English-language, published phase 2/3 studies in PubMed, conference abstracts, and the National Comprehensive Cancer Network guidelines...
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688832/patient-reported-outcomes-in-oncology-drug-labeling-in-the-united-states-a-framework-for-navigating-early-challenges
#8
Alan L Shields, Yanni Hao, Meaghan Krohe, Andrew Yaworsky, Iyar Mazar, Catherine Foley, Faisal Mehmed, Denise Globe
BACKGROUND: Despite an increased use of patient-reported outcomes (PROs) in oncology clinical trials, integrating the patient perspective into drug approval decisions and documentation has been challenging. OBJECTIVES: To review important regulatory and measurement terminology, and to provide oncology outcomes researchers and those involved with building oncology programs with tools to plan PRO data collection, particularly in relation to drug efficacy claims for drug labeling in the United States...
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625741/navigating-the-hassle-map
#9
EDITORIAL
David B Nash
No abstract text is available yet for this article.
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625740/implications-of-real-world-data-and-pharmacoeconomics-for-managed-care
#10
Lilly Ostrovsky
The following summaries represent a sample of the many real-world, evidence-based studies presented at the 28th Annual Meeting of the Academy of Managed Care Pharmacy (AMCP), April 19-22, 2016, in San Francisco, CA. These studies highlight some of the main trends in the current US healthcare with important implications for payers, employers, drug manufacturers, providers, patients, and other healthcare stakeholders.
May 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625739/in-silico-pharmacology
#11
EDITORIAL
David B Nash
No abstract text is available yet for this article.
May 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27606041/will-the-pcsk9-inhibitors-be-employers-line-in-the-sand
#12
Stanton R Mehr
After the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C, employers have become very sensitive to new, and especially unforeseen, factors that significantly raise healthcare costs. With the recent launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, self-insured and fully insured employers have been seeking information on this drug class and its potential for off-label use, which could amount to up to $23 billion in healthcare expenditures, according to a report from Prime Therapeutics...
May 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27606040/increased-burden-of-healthcare-utilization-and-cost-associated-with-opioid-related-constipation-among-patients-with-noncancer-pain
#13
Ancilla W Fernandes, David M Kern, Catherine Datto, Yen-Wen Chen, Charles McLeskey, Ozgur Tunceli
BACKGROUND: Opioids are widely accepted as treatment for moderate to severe pain, and opioid-induced constipation is one of the most common side effects of opioids. This side effect negatively affects pain management and patients' quality of life, which could result in increased healthcare utilization and costs. OBJECTIVE: To assess healthcare utilization and costs (all-cause, constipation-related, and pain-related) for individuals with and without opioid-induced constipation during the 12 months after initiation of opioid therapy for noncancer pain...
May 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27606039/benefits-of-early-roflumilast-treatment-after-hospital-or-emergency-department-discharge-for-a-copd-exacerbation
#14
Qing Lee, Michelle Mocarski, Shawn X Sun
BACKGROUND: Chronic lower respiratory disease, which includes chronic obstructive pulmonary disease (COPD), is the third leading cause of death in the United States. Roflumilast is an oral, once-daily, selective phosphodiesterase-4 inhibitor approved for reducing the risk for COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. OBJECTIVES: To evaluate the effects of roflumilast treatment timing on COPD exacerbation rates (primary objective) and on resource utilization and healthcare costs (secondary objective) after hospital or emergency department discharge associated with a COPD exacerbation...
May 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27606038/the-prevalence-and-determinants-of-controlled-substance-discrepancies-in-a-level-i-trauma-hospital
#15
Chukwuma Anyanwu, Oliver Egwim
BACKGROUND: Healthcare institutions are often faced with challenges and accreditation requirements for improving treatment quality, reducing waste, and avoiding diversion of drugs, particularly controlled substances. Many automated systems have replaced manual systems but may be fraught with challenges, especially when multiple users are involved. OBJECTIVE: To describe the characteristics of controlled substance discrepancies observed in a Level I trauma hospital for Medicare...
May 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27182428/inpatient-utilization-and-costs-for-medicare-fee-for-service-beneficiaries-with-heart-failure
#16
Kathryn Fitch, Pamela M Pelizzari, Bruce Pyenson
BACKGROUND: Although the medical and economic burden of heart failure in the United States is already substantial, it will likely grow as the population ages and life expectancy increases. Not surprisingly, most of the heart failure burden is borne by individuals aged ≥65 years, many of whom are in the Medicare population. The population-based utilization and costs of inpatient care for Medicare beneficiaries with heart failure are not well understood by payers and providers. OBJECTIVE: To create a real-world view of utilization and costs associated with inpatient admissions, readmissions, and admissions to skilled nursing facilities among Medicare fee-for-service (FFS) beneficiaries with heart failure...
April 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27182427/patient-preferences-regarding-rheumatoid-arthritis-therapies-a-conjoint-analysis
#17
Anthony M Louder, Amitabh Singh, Kim Saverno, Joseph C Cappelleri, Aaron J Aten, Andrew S Koenig, Margaret K Pasquale
BACKGROUND: Tofacitinib, an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA), provides patients with an alternative to subcutaneously or intravenously administered biologic disease-modifying antirheumatic drugs (DMARDs). Little is known about patient preference for novel RA treatments. OBJECTIVE: To investigate patient preferences for attributes associated with RA treatments. METHODS: A choice-based conjoint survey was mailed to 1400 randomly selected commercially insured patients (aged 21-80 years) diagnosed with RA, who were continuously enrolled from May 1, 2012, through April 30, 2013, and had ≥2 medical claims for International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code 714...
April 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27182426/patient-characteristics-and-prescribing-patterns-associated-with-sofosbuvir-treatment-for-chronic-hcv-infection-in-a-commercially-insured-population
#18
Brent M Tambourine, Arash Sadeghi, Jianing Yang, Karen M Stockl, Heidi C Lew, Brian K Solow, Josephine N Tran
BACKGROUND: In December 2013, the US Food and Drug Administration (FDA) approved sofosbuvir (Sovaldi) for the treatment of patients with chronic hepatitis C virus (HCV) infection. Given the potential "warehousing" of patients before the launch of sofosbuvir and the possibility that some patients and providers may have elected to continue deferring treatment in anticipation of more promising, interferon-free therapies in the pipeline, the early landscape for sofosbuvir treatment is difficult to ascertain...
April 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27182425/convergence-in-healthcare-providers-employers-and-health-plans
#19
Byron C Scott
No abstract text is available yet for this article.
April 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27668064/competition-heats-up-in-rheumatoid-arthritis-and-other-autoimmune-conditions
#20
Gary Branning
No abstract text is available yet for this article.
March 2016: American Health & Drug Benefits
journal
journal
48448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"